PABAF (Patrys) EV-to-FCF: -10.60 (As of Jun. 27, 2026)


What is Patrys EV-to-FCF?

Patrys PABAF EV-to-FCF is -10.60 as of Jun. 27, 2026. The stock has 1 warning sign investors should review. Among 333 Biotechnology companies, Patrys ranks worse than 300300% on this metric.

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Patrys's Enterprise Value is $16.62 Mil. Patrys's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.57 Mil. Therefore, Patrys's EV-to-FCF for today is -10.60.

The historical rank and industry rank for Patrys's EV-to-FCF or its related term are showing as below:

PABAF' s EV-to-FCF Range Over the Past 10 Years
Min: -10.06   Med: 0   Max: 0
Current: -10.06

PABAF's EV-to-FCF is ranked worse than
100% of 333 companies
in the Biotechnology industry
Industry Median: 14.65 vs PABAF: -10.06

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-06-27), Patrys's stock price is $0.06. Patrys's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.014. Therefore, Patrys's PE Ratio (TTM) for today is At Loss.


Patrys  (OTCPK:PABAF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Patrys's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.06/-0.014
=At Loss

Patrys's share price for today is $0.06.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Patrys's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.014.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Patrys EV-to-FCF Related Terms


Patrys EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Patrys's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Patrys EV-to-FCF Chart

Patrys Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.38 -3.60 -2.86 -6.68 -0.91

Patrys Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -6.68 0.00 -0.91 0.00

PABAF vs VRTX, REGN, ALNY: EV-to-FCF Comparison

For the Biotechnology subindustry, Patrys's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Patrys EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Patrys's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Patrys's EV-to-FCF falls into.



Patrys EV-to-FCF Calculation

Patrys's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=16.615/-1.568
=-10.60

Patrys's current Enterprise Value is $16.62 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Patrys's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-FCF →
What does a EV-to-FCF of -10.60 mean?
Patrys (PABAF) has a EV-to-FCF of -10.60 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Patrys and its competitors. According to the industry distribution chart, Patrys ranks #999999 out of 333 companies in the Biotechnology industry.
Is Patrys' EV-to-FCF too high?
Patrys' current EV-to-FCF is -10.60. Based on the distribution chart, Patrys ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Patrys' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Patrys ranks #999999 out of 333 companies for EV-to-FCF. This places Patrys in the lower half of its industry. The industry median EV-to-FCF is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Patrys and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Patrys's current EV-to-FCF is -10.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Patrys stock overvalued right now?
Patrys (PABAF) has a current EV-to-FCF of -10.60. The current EV-to-FCF is -10.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Patrys (PABAF), the current EV-to-FCF is -10.60 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Patrys Business Description

Other Exchanges PABDA:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3000
Patrys Ltd is a biopharmaceutical company focused on developing novel antibody-based therapies prominently for cancer and related inflammatory diseases. Its core technology platform involves antibodies that penetrate cell nuclei and inhibit cancer cell DNA repair mechanisms. The company advances therapeutic candidates from its antibody platforms, including ones licensed from Yale University, with ongoing preclinical and clinical development activities. Patrys generates revenue through licensing agreements and collaborations linked to its antibody technologies. Its operations and development efforts span Australia and the United States.